Anatara Lifesciences Ltd (ASX:ANR) ABC Video Program - Non-Antibiotic Treatment for Pigs

🕔3/23/2017 6:45:01 PM

An oral drench to protect piglets from gut infection could soon be available to pig farmers. It's been developed by scientists and is made from pineapples - taking antibiotics out of the food chain.

Read Full Article

Rhinomed Ltd (ASX:RNO) Adds US Based Cornerstone Investors and Initiates Capital Management Program

🕔3/15/2017 4:53:14 PM

Rhinomed (ASX:RNO) advises it has undertaken a AUD$2.19 million private placement to two US based sophisticated investor groups as part of its 15% placement capacity. In addition, the company has flagged its intention to hold a General Meeting to approve a capital management initiative that will seek to consolidate the company's capital and provide a sale of less than marketable share parcels facility.

Read Full Article

FINANCE VIDEO: Regeneus Ltd (ASX:RGS) CEO John Martin Talks about the Licensing of Progenza in Japan

🕔3/9/2017 9:00:20 AM

With the recent announcement of a significant licensing deal with AGC Ltd in Japan, the company is set to build on their platform for the delivery of Progenza to deal with many healthcare issues from arthritis and pain, to genetic disorders.

Read Full Article

Rhinomed Ltd (ASX:RNO) Mute Global Distribution Milestone Update

🕔3/8/2017 12:18:23 PM

Rhinomed (ASX:RNO) is pleased to provide an update on the expansion of its global distribution program. The company can report that Rhinomed has been added as a vendor by two major US based pharmacy wholesalers and the successful expansion of the listing of its Mute Sleep technology by Symbion in Australia.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Half Yearly Report and Accounts

🕔2/23/2017 9:20:20 AM

Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide the Company's Half Yearly Report for the period ended 31 December, 2016.

Read Full Article

Immuron Limited (ASX:IMC) Significantly Rerated by European/US Analyst's Report

🕔2/15/2017 10:24:23 AM

Immuron Limited (ASX:IMC) (OTCMKTS:IMROY) wishes to advise investors that European and US-based Life Sciences Research and Analyst firm Van Leeuwenhoeck Institute, has published an updated in-depth Research Report on the Company and its R&D programs.

Read Full Article

Imugene Limited (ASX:IMU) Encouraging HER-Vaxx Research Published in Prestigious BMC Cancer Journal

🕔2/13/2017 11:14:52 AM

Imugene Limited (ASX:IMU) preclinical research related to HER-Vaxx (clinical name IMU-131) has been accepted and published in the prestigious journal BMC Cancer. IMU-131 is a next generation HER-2 cancer therapy using B cell peptides, which harness the body's ability to develop antibodies against the disease.

Read Full Article